论文部分内容阅读
目的 验证可乐定的抗溃疡性结肠炎（ＵＣ） 作用，并为ＵＣ 患者提供一味良好的治疗药物；方法 选择ＵＣ患者１６０ 例，随机分成治疗组和对照组，两组均定时检测结肠粘膜病理改变及临床症状变化，数据记入ＵＣ 追踪治疗记录表作Ｘ２ 检验；结果 可乐定组总有效率为９１ ．２５ ％ ，ＳＡＳＰ 组总有效率为８８ ．７５ ％ ，两组无显著差异（ Ｐ＞ ０ ．０５） ，但可乐定组溃疡愈合率、腹痛缓解率及里急后重消除率均优于ＳＡＳＰ 组（ Ｐ＜ ０ ．０５） ；结论 可乐定确有抗ＵＣ作用，可广泛推广应用，一般应从小剂量开始。
Objective To validate the anti-ulcerative colitis (UC) effect of clonidine and provide a good therapeutic drug for UC patients.Methods 160 patients with UC were randomly divided into treatment group and control group. The pathological changes of colonic mucosa And changes in clinical symptoms, the data recorded in the UC follow-up treatment record table for the X2 test; results clonidine group total effective rate of 91. 25%, SASP group total efficiency of 88. 75% respectively. There was no significant difference between the two groups (P> 0.05), but the rates of ulcer healing, abdominal pain relief and teratogenic and re-emergent rates in the clonidine group were better than SASP group (P <0.05) UC role, can be widely promoted, generally should start with a small dose.